Clinical trials: Carbapenemase-producing Enterobacteriaceae Infections
Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia
Real-World Study of Ceftazidime Avibactam in China
This observational study will enroll approximately 450 in patients. Patients treated with CAZ AVI for at least 1 dose at around 20 research centers in China will be enroll.
- Conditions
- Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia, Complicated Intra Abdominal Infections
- Trial name
- REACT (NCT05487586)
- Testing
- ceftazidime avibactam group
- Where
- 17 sites in China
- Volunteers
- 220 people
- Sponsor
- Pfizer
Septic Shock
Pentaglobin in CRE and PA Neutropenic Infections
To demonstrate that the early addition of Pentaglobin to the best available antimicrobial therapy is able to reduce mortality and improve survival in neutropenic febrile acute leukemia or allo- Hematopoietic stem cell…
- Trial name
- PENTALLO (NCT03494959)
- Testing
- Pentaglobin
- Where
- 20 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Carbapenem-Resistant Enterobacteriaceae Infection
Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection
Colistin can be used to treat the infection caused by carbapenem-resistant enterobacteriaceae(CRE). In China, patients diagnosed with Hospital-acquired-pneumonia (HAP)or bloodstream infection caused by CRE are recruited, and…
- Trial name
- NCT06051513
- Testing
- treatment with or without colistin
- Where
- 15 sites in China
- Volunteers
- 404 people
- Sponsor
- Southeast University, China
Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in…
- Conditions
- Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE, Complicated Urinary Tract Infection (cUTI) Due to CRE
- Trial name
- CARE (NCT01970371)
- Testing
- plazomicin, colistin, meropenem
- Volunteers
- 69 people
- Sponsor
- Achaogen, Inc.
Nfections, Enterobacterial
Infections With Enterobacteria Producing Carbapenemases at the University Hospitals of Strasbourg
Infections with enterobacteria producing carbapenemases at the University Hospitals of Strasbourg - descriptive epidemiology and risk factors for infection in the event of colonization There is a worrying situation of an increase…
- Trial name
- CARBA (NCT04995965)
- Where
- France
- Volunteers
- 274 people
- Sponsor
- University Hospital, Strasbourg, France
Carbapenemase-producing Enterobacteriaceae Infection
Clinical Trial to Demonstrate the Effectiveness of Fecal Microbiota Transplantation for Selective Intestinal Decolonization of Patients Colonized by Carbapenemase-producing Klebsiella Pneumoniae
Infections caused by carbapenemase-producing Enterobacteriaceae are frequent and often associated with high rates of mortality. Colonized patients are at increased risk of infection for these microorganisms.
- Trial name
- KAPEDIS (NCT04760665)
- Testing
- Fecal microbiota transplantation
- Where
- Spain
- Volunteers
- 2 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection
Aztreonam-Avibactam in Immunocompromised Hosts
The goal of this observational study is to learn about the effectiveness and safety of aztreonam-avibactam (ATM-AVI), an antibiotic used to treat infections caused by highly resistant bacteria, in adults with weakened immune…
- Conditions
- Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection, Immunocompromised Host, Drug Resistance, Multiple, Bacterial
- Trial name
- IMMUNO-AVI (NCT07890480)
- Testing
- Aztreonam-Avibactam, Ceftazidime-Avibactam Plus Aztreonam
- Where
- Argentina
- Volunteers
- 814 people
- Sponsor
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Bacterial Sensitivity Tests, Antimicrobial Drug Resistance
AMR-DetecTool for the Diagnostic of MDR Bacterial Infections
The fight against bacteria is one of the greatest challenges faced by societies, especially with the spread of multi drug resistant (MDR) bacteria.
- Trial name
- AMR DetecTool (NCT05378217)
- Testing
- AMR LFIA Assay
- Where
- 3 sites in France, Hungary and 1 more
- Volunteers
- 167 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Carbapenemase-producing Enterobacteriaceae Infections
Cost-effectiveness of Controlling CPE
Spread of extensively drug-resistant bacteria (XDR) such as carbapenemase-producing Enterobacterales (CPE) is a major public health problem.
- Trial name
- OPTIM-BHRe (NCT05272410)
- Volunteers
- 1,800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
The study will evaluate the efficacy and safety of Meropenem and Pralurbactam versus Best Available Therapy in the treatment of Carbapenem-Resistant Enterobacteriaceae Infections.
- Conditions
- Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI), Complicated Urinary Tract Infection (cUTI)
- Trial name
- NCT07089186
- Testing
- Meropenem and Pralurbactam, Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Antibiotic Resistance, Enterobacteriaceae Infections
Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern France
Carbapenemase-producing Enterobacteriaceae (CPE) are classified as emerging Highly Resistant Bacteria (eHRB) because they expose infected patients to the risk of treatment failure due to the strains' resistance to last-line…
- Conditions
- Antibiotic Resistance, Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection, Colonization
- Trial name
- CARBACOLI (NCT07676513)
- Testing
- MultiLocus Sequence Typing
- Where
- France
- Volunteers
- 163 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Clinically Significant Bacteremia
Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to Extended-spectrum Beta-lactamase (ESBL) or Carbapenemase-producing Enterobacteriaceae: an Observational Multinational Study
Main objective: to observationally assess the efficacy of different antimicrobials in Bloodstream Infection (BSI) due to Enterobacteriaceae producing ESBLs or carbapenemases.
- Trial name
- INCREMENT (NCT01764490)
- Where
- Spain
- Volunteers
- 1,344 people
- Sponsor
- JESUS RODRIGUEZ BAÑO
Cirrhosis, Bacterial Infections
International Surveillance of Antimicrobial Resistance in Cirrhosis-Related Infections
What is this study about? This study tracks antibiotic resistance in patients with cirrhosis who develop bacterial infections. Cirrhosis is a condition where the liver is severely scarred, and people with cirrhosis are at high…
- Conditions
- Cirrhosis, Bacterial Infections, Multidrug Resistance
- Trial name
- NCT06634940
- Where
- Argentina
- Volunteers
- 1,000 people
- Sponsor
- Hospital Italiano de Buenos Aires
Intestinal Multi-drug Resistant Organism Colonization
Further MT for Antibiotic-Resistant Bacterial Colonization
The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection.
- Trial name
- FAIR (NCT05835206)
- Testing
- Microbiome Therapeutic
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Infections Resistant to Multiple Drugs, Bacterial Infections
Multi-Drug Resistant Organism Network
This study is specifically designed to provide observational data which can be used to help in the design of future randomized clinical trials on both therapeutics and diagnostics for MDRO infections.
- Trial name
- MDRO Network (NCT03646227)
- Testing
- Standard of Care
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 6,496 people
- Sponsor
- Duke University
Bacteremia, Enterobacteriaceae Infections
Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From Blood
The purpose of this study is to develop a new and very rapid diagnostic test for identifying a certain type of bacteria called Enterobacteriaceae in blood.
- Trial name
- NCT02482051
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Denver Health and Hospital Authority
Carbapenem-Resistant Enterobacteriaceae Infection
Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria
Patients with infections caused by carbapenem-resistant enterobacteria treated with CAZ-AVI versus patients treated with BAT are compared. The BAT group includes fosfomycin, tigecycline, gentamicin, meropenem and colistin.
- Trial name
- CAVICOR (NCT04167228)
- Testing
- Ceftazidime-Avibactam, Best Available Therapy
- Where
- 17 sites in Spain
- Volunteers
- 348 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Clostridium Difficile Infection
Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients
Vancomycin-resistant Enterococcus (VRE) and carbapenem-resistant Enterobacteriaceae (CRE) are multi-drug resistant organisms (MDROs) associated with healthcare settings and are a high priority for containment in public health.
- Trial name
- NCT03643887
- Testing
- FMT Capsule DE
- Sponsor
- University of Wisconsin, Madison
Carbapenem-Resistant Enterobacteriaceae, Lower Respiratory Tract Infections
Correlation Analysis of Xpert Carba-R Detection of Non-colonized CRE in BALF and Rectal Swabs From Patients With LRTI
Assess the correlation between Xpert Carba-R detection of carbapenemase gene types in bronchoalveolar lavage samples and rectal swab samples from non-colonized CRKP patients with lower respiratory tract infections, and evaluate…
- Trial name
- NCT06636890
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Antibiotic Resistant Strain, Microbial Colonization
Fecal Microbiota Transplantation for Eradication of Carbapenem-resistant Enterobacteriaceae Colonization
Antibiotic resistance has emerged world wide and is of major concern. Multidrug resistant (MDR) bacteria is widely spread and is now a major factor in morbidity and mortality in health-care settings.
- Trial name
- NCT03391674
- Testing
- Fecal Microbiota Transplantation
- Where
- Israel
- Sponsor
- Rambam Health Care Campus